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Introduction: Hematopoietic stem cell transplantation (HSCT) is a complex 
procedure, in which stem cells from the bone marrow, peripheral blood or 
umbilical cord are inserted in the recipient. In order for the recipient receive 
these cells without developing Graft versus Host Disease (GvHD), 
immunosuppressive therapy should be followed. A well known drug used in this 
therapy is cyclosporine (Cya), whose mechanism of action is the T cells 
proliferation reduction, by the inhibition of interleukin-2. This drug presents high 
variability in the absorption rate, plus it follows metabolism by the cytochrome 
enzymes. Pharmacokinetic studies in the pediatric population using this drug 
are scarce. There are main differences in the pharmacokinetic parameters 
between solid organs and hematopoietic stem cells recipients. Materials and 
Methods: In this study we reviewed the medical records from the pediatric 
patients at the Hematological Service of the Hospital de Clínicas de Porto 
Alegre. We divided these patients into two groups: a) patients whose Cya levels 
were not used to dose adjustment based on pharmacokinetic analysis (n= 11) 
and b) patients whose Cya levels were used to dose adjustment based on 
pharmacokinetic analysis (n =11). Results: The medical records were accessed 
in order to obtain the patients’ demographics data and other relevant 
information such as renal function, grafting day and Cya mode of use and 
concomitant drugs intake. The indication for the treatment with intravenous (IV) 
Cya was the prophylaxis against GvHD. Most patients from both monitored and 
non-monitored groups presented CyA seric levels between the expected 
therapeutic window (100 ng/ml – 400 ng/ml), however in the literature it was 
found that in the period just after HSCT these levels should be higher (>200 
ng/ml), in order to prevent the GvHD event. Conclusions: We observed that in 
the monitored group the levels out of the therapeutic window were above the 
expected, while in the non monitored group these levels were below the 
accepted ones. Our hypothesis is that due to the Pharmaceutical Service there 
was a better awareness by the health professionals in not letting Cya levels 
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 Hematopoietic Stem Cell Transplantation (HSCT) is the process in which 
an infusion of stem cells, coming from donators, related or not, occurs. The 
stem cells might come from the bone marrow, peripheral blood or umbilical 
cord1. Before the transplantation happens the patient should undergo the 
conditioning regimen, also called chemotherapy, which could be a myeloblative 
or non-myeloblative conditioning, being the last the most preferable. An ideal 
non-myeloablative regimen should allow the grafting process to occur with the 
least post-transplant toxicity, in order to avoid high grades of Graft versus Host 
Disease (GvHD) 2, which is certainly the most important complication from an 
HSCT. Acute GvHD is one of the most frequent mortality causes in patients who 
underwent HSCT. This disease is the immunologic process in which mature 
donor T cells interact with host and donor antigen presenting cells, thus causing 
the release of pro-inflammatory cytokines. These cytokines might later lead to 
host tissue damage by T cell activation 3. 
 
GvHD may occur some days before the grafting or even months later. 
This disease can be acute, in which the symptoms may be dermatological, 
hepatological or gastrointestinal lesions. In chronic GvHD the symptoms might 
be located in only one organ or in many sites1. Thus, due to possible bad 
prognosis, these patients should receive efficient prophylactic therapies in order 
to avoid GvHD occurrence. However, it is also important that the Graft against 
Leukemia process occurs (GvL). A balance between GvHD and GvL might be 
the ideal outcome after HSCT. It was found in the literature that when used 
together, methotrexate and cyclosporine might promote less GVhD cases4. This 
combination is one of the most used in HSCT pediatric centers5, and that was 





Cya is a cyclic peptide which contains 11 amino acids residues with high 
immunosuppressive activity. This mechanism of action is related to the T cells 
proliferation reduction, due to interleukin 2 (IL-2) gene inhibition. Calcineurin is a 
phospatase activated when a T cell interacts with an antigen. This enzyme, 
thus, activates IL-2 production. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Cyclosporine-immunophilin complex binds to and inactivates calcineurin, which 
leads to T helper cells inactivation and, as a consequence, inhibition of IL-2 
production, resulting in an immunosuppressive activity 7. 
 
Cya is a very lipophilic drug with high variability in terms of absorption. It 
presents a large volume of distribution (4 - 5 L/kg), low clearance (5–10 
ml/kg/min)8 and it passes through liver biotransformation, due to cytochrome 
P450 3A4 enzymes9. Pharmacokinetics studies about Cya in the pediatrics 
context are scarce in the literature. Some prospective studies based on this 
population, who underwent HSCT, suggest the dosing regimens of 2 mg/kg 
given intravenously at a constant rate 2 h infusion twice a day5,9. There is a very 
large range of the best serum trough levels to be achieved described in 
literature, depending on covariates such as age, underlying disease, body 
weight, among others. Even though trough levels measurements are the most 
used method in order to estimate pharmacokinetic parameters for patients using 
Cya, there are many studies which have not found this laboratory result to be a 
good dosage predictor. This is observed not only for HSCT patients 5,9,10,11, but 
also for patients submitted to solid organs transplantations12. Even though, 
trough levels measurement is not the best approach in Cya monitoring, this is 
the most used method due to its practical performance11. It is also important to 
relate that there are differences in the pharmacokinetic parameters between 
solid organs transplantation and HSCT 13. Shultz et al 10 reports that children 
and adults who received stem cells presented delayed Cya absorption in 
relation to patients who received solid organs. Moreover, patients who 
underwent HSCT had changes in the gastrointestinal tract, due to inflammation 
processes like mucositis, leading to high Cya exposure. The pediatrics 
population also presents some differences in the pharmacokinetic parameters in 
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relation to adults, which are important to be noticed when studying 
pharmacokinetic models in this population. Newborns undergo fast changes 
due to their maturation process, which causes huge variability in 
pharmacokinetics and pharmacodynamic approaches 14. Neonates and infants 
tend to have a reduced plasma protein binding, what might increase the drug 
distribution in the body. Consequently, this difference in the volume of 
distribution might lead to a wrong interpretation of the drug plasma levels 
measurements. It is recommended that drugs highly metabolized by the liver, 
such as Cya, should be administered with care before the age of 2 months and 
changes in dosing should be ascertained mainly by drug monitoring 15. For 
these reasons drug monitoring techniques development is essential in the 
pediatric population who underwent HSCT using Cya as prophylaxis against 
GvHD.  
 In the present study, demographical characterization of the HSCT 
pediatric patients treated at Hematological Service of the Hospital de Clínicas 
de Porto Alegre, who received cyclosporine during the period from January 
2015 to October 2017 was described and the impact of dosing adjustments of 
intravenous Cya was evaluated.    
 
Methods 
Study design and population  
 The study was performed at Hospital de Clínicas de Porto Alegre 
(HCPA), a general hospital located in Porto Alegre city, Brazil. The data was 
collected retrospectively in the platform called AGHuse from patients aged 0 – 
14 years of age, who were given intravenously Cya between January 2015 and 
November 2017 in order to prevent the GvHD development following HSCT. 
Patients were selected by a search in the platform AGHuse by drug, route of 
administration and hospital ward. Pediatric patients who were taking Cya, but 
did not undergo HSCT at HCPA were excluded.  The patients (n = 22) were 
split in two groups: a) patients whose Cya levels were used to dose adjustment 
with empirical analysis (11) and b) patients whose Cya levels were used to dose 
adjustment with pharmacokinetic analysis (11). A total of 180 whole blood levels 
of Cya were evaluated. Both patients’ populations were statistically equal in 
terms of age and weight. This fact was verified by the non-parametric Mann 
6 
 
Whitney U test, whose U value for weight was equal to 36 and the U value 
calculated for age was equal to  47 (p = 0.05). The study was approved by the 
Research Ethics Committee of Federal University of Rio Grande do Sul and 
HCPA (#2.672.571). In Figure 1 it can be observed a scheme with the steps 
followed for the patients’ data collection.  
 
Review of medical record 
 The medical records found in AGHuse Platform were accessed in order 
to obtain the patients’ demographics data (age, gender, weight, diagnostic 
disease) (Table 1) and other relevant information such as renal function, 
grafting day and Cya mode of use and concomitant drugs intake (Table 2). The 
concomitant drugs were chosen based on their capacity of changing Cya serum 
levels and frequency of use by the studied population. Thus, data from 
omeprazole, fluconazole, metronidazole and trimethoprim/sulfamethoxazole   
therapies were also accessed. 





















































  Yes No    
1 M AML x   9 45.45 
2 F ALL /AML x   14 59.93 
3 F ALL x   1 7.06 
4 F ALL x   8 25.53 
5 F ALL x   14 61.94 
6 F MDS x   9 32.59 
7 M ALL x   3 15.74 
8 F SCID x   1 10.95 
9 F HLH x   11 54.9 
10 M SCA/BT x   9 25.21 
11 M LL x   8 39.34 
MEAN ______ ______ ______ ______ 7.9 34.42 
12 F ALL/MDS   x 5 22.53 
13 M ALL   x 8 23.00 
14 M ALL   x 5 26.44 
15 F AG/NSI   x 6 16.33 
16 M ALL/AML   x 1 11.52 
17 M ALL / MDS   x 14 32.34 
18 M HIES/AML   x 1 10.57 
19 F AML   x 4 18.9 
20 M AML/ALL   x 14 41.42 
21 M HIgMI   x 10 24.94 
22 F MDS/AML   x 1 10.72 
MEAN ______ ______ ______ ______ 6.27 21.70 
MEAN ______ ______ ______ ______ 7.09 28.06 
 *ALL = acute lymphoblastic leukemia AML= acute myeloid leukemia NSI = non-specific 
 immunodeficiency MDS = myelodysplasic syndrome HLH = hemophagocytic 
 lymphohistiocytosis  HIES= hyperimmunoglobulin E syndrome SCID = severe 
 combined immunodeficiency SCA =  sickle cell anemia BT= beta thalassemia 
 LL= lymphoid leukemia HIgMI= hyperimmunoglobulin M  immunodeficiency   AG 
 = agranulocytosis  
  
 As it can be observed in Table 1, in the monitored group (patients 1 – 11) 
there were 4 boys and 7 girls. The average age of the studied patients was 7.9 
years and they weighed in average 34.42 kg. In the non-monitored group 
(patients 12 – 22) there were 7 boys and 4 girls. Their average age and weight 
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were, respectively, 6.27 years and 21.70 kg.  81.82% patients in each group 
were diagnosed with a malignant disease. 
  In Table 2 we can observe that in the monitored group by 
pharmacokinetic equations (patients 1 – 11) the           average serum 
creatinine range was 0.28 – 0.67 mg/dL and in the non-monitored group by 
pharmacokinetic equations (patients 12 – 22) was 0.19 – 0.53 mg/dL. The 
reference value for seric creatinine is found in a range between 0.5 – 1.0 mg/dL 
for children aged 3 to 18 years old, while the range is between 0.3 – 0.7 mg/dL 
for children under 3 years old16. Drugs such as omeprazole, fluconazole, 
metronidazole and trimethoprim/sulfamethoxazole might be able to interfere 
with CyA levels.  Frequently the patients from both groups had to take some of 
these drugs during CyA intravenous therapy. Fluconazole and 
trimethoprim/sulfamethoxazole are recommended by the hospital’s protocol. 
Fluconazole is a prophylatic treatment against various fungi infections, while 
trimethoprim/sulfamethoxazole is used against Pneumocystis carinii infection 6. 
Both omeprazole and metronidazole were not recommended by the current 
hospital protocol.  Table 2 shows that 63.64% of the total number of patients 
used omeprazole during CyA IV therapy, while 86.36 % took fluconazole during 
this period, 86.36% metronidazole and only 18.18 % had to take 
trimethoprim/sulfamethoxazole during the same period. Only two of the patients 
had to use the four drugs during CyA IV therapy and both of them are part of 
the monitored group.  
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Table 2: Patients’ data related to renal function, grafting process and use of Cyclosporine and concomitant drugs. 







IV route  
Drugs used during CyA intravenous therapy  
  IV   IV Oral   OMZ FCZ MTZ TMP -SMT 
1 AML 0.3 – 0.44 D + 13 x x 15 x x ______ ______ 
2 ALL /AML 0.25 – 0.49 D + 24 x x 30 x x x ______ 
3 ALL 0.17 D + 34 x x 41 ______ x x ______ 
4 ALL 0.17 – 0.33 D + 21 x x 29 x x x ______ 
5 ALL 0.69 -1.23 ______ x ______ 17 x ______ x ______ 
6 MDS 0.2 – 0.37 D + 15 x x 28 ______ x x ______ 
7 ALL 0.17 – 0.37 D + 25 x x 40 x x ______ x 
8 SCID 0.17 – 0.29  D + 22 x x 29 ______ x ______ ______ 
9 HLH 0.54 – 1.57 ______ x ______ 17 ______ x x ______ 
10 SCA/BT 0.17 – 0.31 ______ x ______ 24 x x x x 
11 LL 0.23 – 1.78  D + 22 x x 27 x x x x 
MEAN 
 
0.28 – 0.67 
   
27 
    
12 ALL/MDS 0.17 - 0.91  D + 31 x x 27 ______ x x ______ 
13 ALL 0.16 – 0.22 D + 22 x x 25 x x x ______ 
14 ALL 0,17 -  0.21 D + 17 x x 24 x x x ______ 
15 AG/NSI 0.17 -  2.00  D + 29 x x 32 x x x ______ 
16 ALL/AML 0.17 – 0.33  D + 18 x x 25 ______ x x ______ 
17 ALL / MDS 0.21 – 0.56  D + 20 x x 21 x x x ______ 
18 HIES/AML 0.17 – 0.24 D+ 17 x x 27 x x x ______ 
19 AML 0.17 – 0.19 D + 14 x x 15 ______ x x x 
20 AML/ALL 0.23 – 0.34 D + 15 x x 16 x x x ______ 
21 HIgMI 0.27 – 0.48 D + 15 x x 26 x x x ______ 
22 MDS/AML 0.17 – 0.3  ______ x x 38 ______ x x ______ 
MEAN 
 
0.19 – 0.53 
   
25.09 
    
MEAN ______ 0.23 – 0.60 ______ 26.05 ______ 
  *OMZ = omeprazole, FCZ = fluconazole, MTZ = metronidazole, TMP-SMT = trimethoprim/sulfamethoxazole 
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Method for quantification of Cya in serum  
 The blood samples were collected from pediatric patients by the nursery 
service, in tube containing EDTA, and the immunoassay method was used for 
quantification of Cya levels in the whole blood of patients by using the Architect 
ci4100 system (Abbot®). The measurement range for drug’s levels in this 
system is between 25 – 1500 ng/mL.  
 
Evaluation of the agreement of the cyclosporine seric levels after 
intravenous intake 
 According to the HCPA’s Allogenic Hematopoietic Stem Cell 
Transplantation Protocol, Cya administration in HSCT pediatric patients starts 
two days before transplantation (D-2) by continuous infusion of 24 h, with the 
first dose defined by body weight (2 mg/kg). This drug is usually combined with 
metotrexate and cyclosporine target for steady-state level is defined in the 
range of 100-400 ng/mL. The value of volume of distribution was assumed as 4 
- 5 L/kg and the bioavailability was 0.308. Based on the dose administered and 
levels of Cya determined in the patients (Css), the pharmacokinetics parameters 
were calculated by the equations showed in the Figure 2 and the 
pharmacokinetic parameters values estimated for each patient are shown in 

















Figure 2: Strategies for Cya dose adjustment by intravenous dosing: 
 
Protocol recommendations Dose adjustment by Hospital 
Pharmacy Service 
 
Based on the Cpss levels of Cya 
determined in the blood, if the values 
achieved were between:  
 0-100 ng/mL increase the dose in 
50%; 
 400-500 ng/mL decrease the 
dose in 25%; 
 500-600 ng/mL stop the 
administration up to 12 h and 
restart with 50% of the last dose. 
 






































A total of 22 pediatric patients had their medical records relating to 
intravenous Cya prescription analyzed. All these patients started to receive Cya 
intravenously 2 days before HSCT, according to the protocol used in the 
hospital where the medical records were searched. In this population, eleven 
patients received this prophylactic treatment after January 2017 which means 
they had their Cya levels and symptoms also reviewed by the Clinical Pharmacy 
Service. Their results were compared to other 11 patients who did not have 
their Cya levels monitored by the Clinical Pharmacy Service and had the dose 
adjustment based on the Hospital protocol (Figure 2). The patients were 
submitted to Cya IV with 24 hours infusion in average during 26 days, which 
corresponds to 173 samples.  For the patients who had the Cya levels 
monitored the average of days using Cya IV was 27 days and 84 samples. On 
the other hand the patients who did not have the CyA levels monitored by the 
Clinical Pharmacy Department used Cya IV during, in average, 25 days and 89 
samples were collected. The indication for the treatment with Cya IV was the 
prophylaxis against GvHD that occurs frequently in patients who undergo 
HSCT. According to the hospital protocol Cya IV is the first choice as a 
pharmacological prophylaxis for this disease.  
A total of 19 studied patients had their medical records accessed in 
relation to the treatment with oral cyclosporine. From these patients 8 of them 
received the treatment with oral Cya after January 2017, while 11 had this 
treatment before this period. The patients received the treatment with oral Cya 
when they had clinical conditions that favored this change in route of 
administration. All the patients selected for this study were taking intravenous 
Cya before oral Cya.  
  The averages for the values of some laboratory exams that might be 
affected due to the intake of CyA were also made. It was found that they were 
very similar between both of the groups and the references values. The mean of 
the potassium levels was 4.20 mEq/L for the monitored and 4.24 mEq/L for the 
non-monitored group, whereas the reference value is a range between 3.6 and 
5.0 mEq/L. Magnesium mean value was 1.79 mg/dL for the monitored group 
and 1.77 mg/dL for the non-monitored patients, and the reference value is 
between 1.9 and 2.5 mg/dL. The hepatic function for the patients was also 
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verified based on the AST and ALT mean levels. AST and ALT means were 
equal to 36 U/L and 37.43 U/L, respectively, for the monitored group; while AST 
mean value was 39.55 U/L and ALT mean value was 53.22 U/L in the non-
monitored group. The reference values for AST in men are between 17 – 59 U/L 
and for women between 14 – 36 U/L. The reference values for ALT for men are 
between 21- 72 U/L and for women 09 – 52 U/L.  Total bilirubin was also 
verified because the levels of this compound might indicate hepatic GvHD. The 
mean of the bilirubin levels for the monitored group was equal to 0.56 mg/dL 
and 0.43 mg/dL for the non-monitored group, whereas the reference value is in 
a range between 0.3 – 1.0 mg/dL 17. 
   
Figure 4: Cya whole blood concentrations (ng/ml) measurements in the 
samples with and without TDM (therapeutic drug monitoring based on 
pharmacokinetic analysis) during the whole treatment. Shaded area indicates 
the expected Cya concentrations (ng/ml). 
 
 
The patients who received the treatment with intravenous Cya after 
January 2017 showed a mean value of 99. 42 ng/ml, while the patients who had 
their data collected before January 2017 presented a mean value equal to 
127.27 ng/ml. These values should be between 100 – 400 ng/ml. Even though, 
according to the therapeutic window settled, 99.42 ng/ml is an adequate 



































Number of samples (n) 
NS measured without TDM (ng/mL) NS measured TDM(ng/mL)
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Graph 1 it can be observed that 9 values from the 84 monitored group samples 
were above the maximum expected of 400ng/ml. Only 2 values of the same 
group were under the minimum expected value of 100ng/ml. Whereas for the 
non-monitored group there were 89 samples, 5 of these were above the 
expected number. On the other hand, 10 of these values were below 100 
ng/mL.  
  In Table 3 it can be observed the estimated pharmacokinetic parameters 
such as clearance (CL), volume of distribution (Vd) and constant of elimination 
(ke) for each patient. For the patients who had their Cya levels monitored (1 – 
11) the mean of the CL range is 8.17 – 23.66 L/h and the mean for the Vd range 
is 77.94 – 82.48 L. The average for the ke for these patients is 0.22 h-1.These 
values were similar to the patients who did not have their CyA levels monitored 
(12 – 22) who presented the average of CL range of 7.26 – 26.84 L/h and a 
range of Vd equal to 49.39 – 51.79 L. The average for the ke parameter is equal 
to 0.26 h-1 for the non-monitored group. These pharmacokinetic parameters 
averages from both groups presented values according to the one showed in 





















Table 3: Pharmacokinetic parameters estimate in the studied patients. 
Patient Code CL range (L/h) Vd (L) range Ke mean (h-1) 
1 14.95 – 24.34 106.12 – 106.47 0,17893 
2 8.96 – 43.81 137.36- 141.57 0,16111 
3 3.75 – 20.39 15.44 – 17.48 0,43947 
4 3.04 – 14.36 57.80 – 60.84 0,14938 
5 8.74 – 16.00 132.68 – 149.18 0,08613 
6 13.41 – 25.12 74.88 – 78.39 0,23762 
7 4.37 – 17.57 36.04 – 39.55 0,22152 
8 2.68 – 24.78 23.40 – 26.21 0,33727 
9 15.80 – 18.88 128.47 0,13496 
10 6.19 – 21.65 57.92 – 60.84 0,23464 
11 7.96 – 33.36 87.28 – 98.28 0,2565 
Mean 8.17 – 23.66 77.94 – 82.48 0.2216 
12 9.92 – 22.40 50.31 – 53.35 0.33667 
13 8.16 – 29.63 52.65 – 54.05 0.26673 
14 4.98 – 7.99 60.37 – 64.35 0.09703 
15 5.79 – 26.44 36.97 – 38.61 0.36699 
16 1.68 – 9.01 26.56 – 27.03 0.20562 
17 10.22 – 32.97 73.48 – 76.05 0.20599 
18 2.7 – 10.68 23.99 – 26.26 0.25414 
19 9.74 – 21.93 44.23 0.35802 
20 15.61 – 91.78 93.83 – 98.98 0.33531 
21 9.65 – 26.55 56.86 – 60.84 0.22924 
22 1.70 – 15.82 23.99 – 25.97 0.24254 
Mean 7.29 – 26.84 49.39 – 51.79 0.26348 
Overall mean 7.71 – 25.25 63.67 – 67.14 0.24254 
 
Graph 2 shows us that most patients from both monitored and non-
monitored groups have Cya seric levels between the expected therapeutic 
window (100 ng/ml – 400 ng/ml), however in the literature it was found that in 
the period just after HSCT these levels should be higher (>200 ng/ml), in order 
to prevent the GvHD event 18. 46.15% patients from the non-monitored group 
presented Cya levels lower than 200 ng/ml until D+10, while 50% patients from 







Figure 5: Cya whole blood concentrations (ng/ml) measurements in the 
samples with and without TDM until D+10. Shaded area indicates the expected 





















































Number of samples (n)
NS measured without TDM (ng/mL) NS measured TDM(ng/mL)
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Table 4. Cyclosporine pharmacokinetic parameters estimated for the pediatric 
population 8. 
Parameter Value 






Oral bioavailability (%) 30 
Volume of distribution (L/kg) 4 – 5  
Clearance (ml/kg/min) 5 - 10 
Free  fraction (%) 10 




Even though Cya is the first choice drug in many hospitals to prevent 
GvHD, there is still a lack of certainty about how to better predict their serum 
levels after HSCT in children.  It is already well known that trough levels do not 
represent the best approach to estimate the ideal dose for these patients, when 
taking oral Cya. In our study it was seen that both groups (monitored and non-
monitored) presented steady state levels not in accordance with the target one. 
Moreover, it is important to relate that pediatric patients present some important 
differences in pharmacokinetic parameters in comparison to adults, which might 
as well make it more difficult to assure whether the right dose is been given. Lu 
et al15 provide us with information related to the volume of distribution for 
children, which is, in general, higher than for adult patients, due to a reduced 
plasma protein binding. There are also differences in the patients who receive 
solid organs and hematopoietic stem cells. The stem cell recipients tend to have 
more damage in gastrointestinal tract than the solid organs recipients. This 
damage might affect the rate of absorption of drugs. Mucositis, a common 
inflammation in HSC recipients, might increase Cya exposure. As stated in 
Table 1 there is a high use frequency of some drugs in patients submitted to 
HSCT. In our sample these drugs were omeprazole, fluconazole, metronidazole 
and  trimethoprim/sulfamethoxazole. Fluconazole, for example, is able to inhibit 
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the enzyme CYP 3A4, leading to high Cya concentrations in the patient 8, while 
trimethoprim/sulfamethoxazole might cause renal damage, thus decreasing Cya 
effects19. 
In our study we observed in Graph 1 that both monitored and non-
monitored patients by pharmacokinetic equations did not have differences in 
number of serum levels between the accepted therapeutic window. However it 
was clear that, in the monitored group, most of the levels found not to be in 
accordance, were above the expected, while in the non monitored group the not 
correct levels were in many cases below the accepted one. This could be 
related to a better awareness from the pharmaceutical and medical 
professionals to not let Cya levels stay below 100 ng/ml, as this might hugely 
increase the probability of developing GvHD. On the other hand, due to Cya 
pharmacokinetic characteristics and HSC pediatric recipients conditions, higher 
levels of this drug might induce a very compromising toxicological process. In 
Graph 2 we can observe that TDM was not able to let Cya serum levels just 
after HSCT above 200 ng/ml, as around half of the patients from both groups 
presented Cya levels under this target. Higher CyA levels in a short period after 
HSCT are known in the literature to hugely increase the protective effect against 
GvHD in patients 18. As presented in Table 3 the pharmacokinetic parameters 
from both groups seem to be adequate in relation to the reference values for 
this drug 8.   
In order to improve the drug monitoring service conceived by the Clinical 
Pharmacy Department we suggest a pharmacokinetic population modeling to 
be implemented in the HSCT service in HCPA. Even though there could be 
some limitations to implement this approach, such as many levels 
measurements, this strategy might provide accurate results. Costs with staff 
and number of hours spent to provide a result that would cause an impact on 
the dosing process for these patients are very relevant and necessary in a huge 
hospital reality such as HCPA. A pharmacokinetic model is, thereby, able to 
provide an understanding in how the drug exposure is and what consequences 
might be present after its administration in relation to dosing, route and patient’s 
conditions. In a population model we will evaluate how the drug works for each 
subject and then the parameters measured will be compared between the 
studied individuals and subjects from other studies, but with similar clinical and 
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pharmacological conditions 20. Willemze et al 9 showed that determination of 
AUC (area under the curve) with a two point limited sampling strategy might be 
an adequate model to preview the cyclosporine exposure in a similar 
population. For example, with the time-points sampling 0,1,3 or 0,2,3 the r2 in 
both cases was equal to 0.99, which demonstrates that with only 3 samples 
from each patient it is possible to know the accurate Cya exposure. We also 
suggest that a prospective study should be made, in order to better analyze the 
following procedures taken by the prescriber after a level out of the therapeutic 
window.   
 
Conclusions 
 Our project found some limitations in relation to the number of patients 
and the accuracy associated to a retrospective study. There are certainly many 
possible aspects in our patients that might interfere in Cya levels. A review 
about the initial Cya dose in HSCT patients could be made, as most of the 
patients were not able to achieve an adequate level for the short period after 
HSCT. A prospective study should be done in order to provide the necessary 
information to verify if the suggested dosages based on the pharmacokinetic 
equations by the Clinical Pharmacy Service were accepted by the prescriber.  
Further strategies based on population pharmacokinetic modeling studies 
could also be implemented for a more ascertained dosing approach. Other 
drugs that could interfere in cyclosporine levels should also be described, as the 
studied population need to deal with a large variety of drugs, most of them 
affecting Cya levels. The dosage is primarily adjusted based on the patient’s 
weight, which might be the best choice. A better control over the sampling 
process during the drug monitoring step and the engagement of all staff in the 
process could aid to overcome the failures associated to the level results of Cya 
in these patients. Furthermore, it is important to relate more drugs hugely used 
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